Research and Markets - Depression Epidemiology and Patient-Based Market Forecasts 2016 Featuring Lundbeck, Allergan and Johnson & Johnson

DUBLIN, August 17, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Depression: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

The depression market is likely to recover from a new low in 2016, although the extent of its resurgence will depend on the fate of high-risk clinical trials.

This report addresses the following questions:

- How much value remains in the depression market, now that the patent cliff has passed?
- As Lundbeck and Allergan go head-to-head in the SSRI and atypical antipsychotic classes, which of their new brands will become future market leaders?
- What is the potential for Johnson & Johnson's esketamine as an antidepressant, considering its safety profile and regulatory barriers?
- Which new and pipeline drugs address real unmet needs, contrasting with those that can be considered as me-too products?
- How does real-world prescribing behaviour match treatment guidelines for major depression and dysthymia?

Key Topics Covered:

FORECAST: DEPRESSION

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Abilify (aripiprazole)
- Brintellix (vortioxetine)
- Cymbalta (duloxetine)
- esketamine
- Fetzima (levomilnacipran)
- Latuda (lurasidone)
- Lexapro (escitalopram)
- Pristiq (desvenlafaxine)
- Rexulti (brexpiprazole)
- Seroquel (quetiapine)
- Viibryd (vilazodone)
- Vraylar (cariprazine)
- Primary Research Methodology

TREATMENT: DEPRESSION

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Depression

EPIDEMIOLOGY: DEPRESSION IN THE US, JAPAN, AND 5EU

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast: Major Depressive Disorder
- Forecast: Dysthymia
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: DEPRESSION

- Executive Summary
- Product Overview
- Product profile: Abilify
- Product profile: Brintellix
- Product profile: Cymbalta
- Product profile: Fetzima
- Product profile: Lexapro
- Product profile: Pristiq
- Product profile: Rexulti
- Product profile: Seroquel XR
- Product profile: Viibryd

PIPELINE: DEPRESSION

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): ALKS 54
- Product profile (late stage): Vraylar
- Product profile (late stage): esketamine

APPENDIX

- Appendix: Marketed Drugs: Depression
- Appendix: Pipeline: Depression

For more information about this report visit http://www.researchandmarkets.com/research/hpjp9n/depression

Related Topics: Mental Disorders Drugs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]